Last €17.43 EUR
Change Today +0.408 / 2.40%
Volume 0.0
3M4 On Other Exchanges
As of 9:34 AM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

masimo corp (3M4) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/23/14 - €23.31
52 Week Low
05/9/14 - €15.83
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MASIMO CORP (3M4)

masimo corp (3M4) Related Businessweek News

No Related Businessweek News Found

masimo corp (3M4) Details

Masimo Corporation, a medical technology company, develops, manufactures, and markets various noninvasive patient monitoring products worldwide. The company offers Masimo Signal Extraction Technology (SET), which provides the capabilities of measure-through motion and low perfusion pulse oximetry to address the primary limitations of conventional pulse oximetry; and Masimo rainbow SET products that monitor multiple blood measurements, including oxygen content, carboxyhemoglobin, methemoglobin, hemoglobin, pleth variability index, respiration rate, Halo Index, and In Vivo Adjustment. It develops, manufactures, and markets a family of patient monitoring solutions comprising monitors, circuit boards, sensors, and cables; Root, a patient monitoring and connectivity platform; Masimo Patient SafetyNet, a remote monitoring and clinician notification solution; and various software products. The company also provides line filters, cannulas, and mainstream adapters; and wafer epitaxy, foundry, and device fabrication services to biomedical, telecommunications, consumer products, and other markets, as well as develops and manufactures ultra-compact mainstream and sidestream capnography, and gas monitoring technologies. Masimo Corporation sells its products to hospitals, emergency medical response organizations, physician offices, veterinarians, long term care facilities, consumers, and alternate care market through its direct sales force and distributors, as well as to original equipment manufacturer partners. The company was founded in 1989 and is headquartered in Irvine, California.

3,139 Employees
Last Reported Date: 02/14/14
Founded in 1989

masimo corp (3M4) Top Compensated Officers

Founder, Chairman and Chief Executive Officer
Total Annual Compensation: $712.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $334.4K
President of Worldwide Oem Business & Corpora...
Total Annual Compensation: $335.7K
President of Worldwide Sales & Marketing and ...
Total Annual Compensation: $332.4K
Chief Information Officer
Total Annual Compensation: $329.2K
Compensation as of Fiscal Year 2013.

masimo corp (3M4) Key Developments

Arkansas Heart Hospital Upgrades to Masimo SET Pulse Oximetry

Masimo announced that Arkansas Heart Hospital has upgraded hospital-wide to Masimo SET pulse oximetry, leading to a dramatic reduction in false alarms and a significant increase in patient satisfaction. Arkansas Heart Hospital embraces the patient-safety suggestions of leading health organizations, including the Anesthesia Patient Safety Foundation, the Joint Commission, and the Institute for Safe Medication Practices (ISMP), which recommend continuous oxygenation and ventilation monitoring in patients receiving opioid-based pain medications. Opioid analgesics are associated with adverse effects and cause respiratory depression in 0.50%, or 25 of every 5,000 post-surgical patients. Arkansas Heart Hospital officials say that the previous pulse oximetry technology they used (Nellcor) created too many false alarms -- one of the top technology hazards in hospitals today, according to the ECRI Institute. Responding to actionable alarms is critical to prevent patient injury or death, but the frequency of false alarms can increase workload and desensitize clinicians to all alarms, putting patients at risk. Patients at Arkansas Heart Hospital noticed the silence, which helped the hospital improve its Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) scores -- a national, standardized, publicly reported 27-item survey instrument and data collection methodology for measuring patients' perceptions of their hospital experience. Masimo SET(R) Measure-through Motion and Low Perfusion(TM) pulse oximetry technology has been proven by more than 100 independent and objective studies and used on more than 100 million patients a year in leading hospitals worldwide, including the top 10 on the U.S. News & World Report Best Hospitals Honor Roll (2014-2015). Multiple studies have shown that Masimo SET(R) significantly reduces false alarms (specificity), and accurately detects true alarms (sensitivity) compared to non-Masimo SET(R) pulse oximeters. In addition, in a study at Dartmouth-Hitchcock Medical Center in a 36-bed orthopedic unit covering 2,841 patients and 9,978 monitored days over 10 months, the implementation of Masimo SET(R) bedside pulse oximetry and Masimo Patient SafetyNet(TM) resulted in over every 1,000 discharges, patients who were not continuously monitored had 3.4 rescue activations, while patients monitored continuously with Masimo SET(R) had 1.2 rescue activations -- a 65% reduction. Over every 1,000 patient days, patients who were not continuously monitored had 5.6 ICU transfers, while patients monitored continuously with Masimo SET(R) had 2.9 ICU transfers -- a 48% reduction. Dartmouth-Hitchcock estimated cost savings of $58,459 savings per patient not transferred to the ICU, for a annualized savings over $1.5 million annually.

Masimo Announces Two New Clinical Studies Show Masimo Noninvasive Hemoglobin Demonstrated Similar Precision as Hemoglobin from Point of Care Devices

Masimo announced two new studies that showed that noninvasive hemoglobin demonstrated similar accuracy as hemoglobin measured by invasive hemoglobin analyzers when both SpHb and the invasive hemoglobin analyzer were compared to laboratory hematology analyzer. The first study was presented at the American Society of Anesthesiologists (ASA) Annual Meeting in New Orleans, the gathering of anesthesiologists in the world, in patients undergoing potential high blood-loss surgery. Masimo SpHb showed similar absolute and trending accuracy as hemoglobin values determined by a laboratory blood gas analyzer, when both the SpHb and the hemoglobin from the blood gas analyzer were compared to hemoglobin from a laboratory hematology analyzer. At the University of West Paulista (UNOESTE), Presidente Prudente, Brazil, Dr. Edmundo P. Souza Neto and colleagues compared absolute and trending accuracy of hemoglobin values from SpHb (Masimo Radical-7 Pulse CO-Oximeter and SpHb adhesive sensor, Revision K) and an invasive laboratory blood gas analyzer (Cobas B221, Roche Diagnostics, Indianapolis, USA) to hemoglobin values from a hematology analyzer (XE-2100, Sysmex, Kobe, Japan). While blood gas analyzers (also referred to as CO-Oximeters) and hematology analyzers are both laboratory devices that analyze blood samples to determine quantitative hemoglobin values, their methodologies are different and according to prior studies, their values are not interchangeable. In 33 patients, arterial blood gas samples were obtained 15 minutes after the incision, after each bleeding event (loss of at least 400 ml of blood in 40 minutes), and at the end of the surgery. A total of 69 arterial blood gas analyzer-determined hemoglobin values and 69 hematology analyzer-determined hemoglobin values were recorded. SpHb values were available continuously throughout the case and were recorded each time that arterial blood gas samples were obtained. Absolute accuracy was evaluated by comparing the SpHb and arterial blood gas hemoglobin values to the hematology analyzer hemoglobin values. The bias, or average difference, when compared to the hematology analyzer was -0.8 g/dL for SpHb and -1.4 g/dL for the invasive blood gas analyzer. The standard deviation, or maximum difference in approximately 68% of comparisons, was 1.3 g/dL for SpHb and 1.2 g/dL for the invasive blood gas analyzer. Outliers were defined as values >1 g/dL from hematology analyzer. There were fewer SpHb outliers (43%) than blood gas analyzer outliers (69%). Trend accuracy was evaluated by calculating the change in SpHb and change in hemoglobin from the blood gas analyzer and comparing the values to changes in hemoglobin from the hematology analyzer. The trend accuracy sensitivity of SpHb and the blood gas analyzer was determined by analyzing the percentage of time each method had the same directional trend as the hematology analyzer. There were no statistically significant differences between the two test methods for absolute accuracy (p=0.08) or for trending accuracy (p=0.6). For both devices, manufacturer instructions were followed to minimize recording variability and all readings were performed by a single operator, who collected an invasive venous sample and three SpHb measurements on 141 pregnant women aged 19 to 46 years. Venous samples were used to obtain three replicate hemoglobin measurements on the HemoCue Hb 201+ and a single hemoglobin measurement from a hematology analyzer. Compared to the hematology analyzer, researchers found a bias and standard deviation of 1.18 g/dL, +/-1.19 g/dL for the Pronto-7 and 0.01 g/dL, +/-1.34 g/dL for the HemoCue Hb201+. The Pronto-7 demonstrated higher repeatability than the Hemocue Hb 201+, as evidenced by a lower coefficient of variation % of (2.3% vs. 5.2%). Radical-7 and Pronto-7 are monitoring devices. They are not intended to be used as standalone diagnostic devices.

Masimo Announces New Clinical Study Presented at the American Society of Anesthesiologists Annual Meeting Shows Benefit of Oxygen Reserve Index, ORI

Masimo announced that a new clinical study evaluating Masimo's latest noninvasive patient monitoring parameter, Oxygen Reserve Index ORI, showed that ORI can provide advanced warning of potential hypoxia and may help clinicians optimize oxygenation before and during prolonged intubation. The study was among 12 selected from more than 1,000 as one of the Best Abstracts at the American Society of Anesthesiologists (ASA) Annual Meeting in New Orleans, the gathering of anesthesiologists in the world. At the University of Texas Southwestern and Children's Medical Center in Dallas, Dr. Peter Szmuk et al., used ORI to track oxygen available in the lungs during pre-oxygenation, safe apnea, and re-oxygenation. Investigators noted, "Since pre-oxygenation can cause oxygen saturation at 100% for variable durations, this study would aid in the development of an advance indication of desaturation. Pulse oximetry (SpO(2)) provides noninvasive and continuous visibility to arterial blood oxygenation in hypoxia (less than normal oxygenation) and normoxia (normal oxygenation). During supplemental oxygen administration, clinicians often use the partial pressure of oxygen (PaO(2)), which is intermittent and delayed, to monitor levels of hyperoxia (higher than normal oxygenation). Between invasive sampling, changes in PaO(2) cannot be assessed and therefore unexpected hypoxia or unintended hyperoxia can occur. ORI, Masimo's 11th rainbow(R) parameter(2), provides real-time visibility to oxygenation status in moderate hyperoxic range (PaO(2) of approximately 100 to 200mmHg). ORI is intended to supplement, not replace, SpO(2) monitoring and PaO(2) measurements. As an "index" parameter with a unit-less scale between 0.00 and 1.00, ORI can be trended and has optional alarms to notify clinicians of changes in a patient's oxygen reserve.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
3M4:GR €17.43 EUR +0.408

3M4 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CAS Medical Systems Inc $1.76 USD +0.0934
CONMED Corp $41.03 USD +1.01
Hutchinson Technology Inc $3.54 USD +0.05
Integra LifeSciences Holdings Corp $49.72 USD +0.235
LiDCO Group PLC 13.50 GBp +0.25
View Industry Companies

Industry Analysis


Industry Average

Valuation 3M4 Industry Range
Price/Earnings 20.9x
Price/Sales 2.3x
Price/Book 3.8x
Price/Cash Flow 19.9x
TEV/Sales 1.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MASIMO CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at